Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an Overweight rating on shares with a $25 price target, following Goldman Sachs adding the firm to its Conviction Buy List yesterday. Shares are down 1.4%, standing as the leader for Dow components on the day.